I have always believed that one of the reasons this stock is subject to long flat periods and then dramatic jumps is that the analysts that cover it really don't understand and accept common wisdom until they get surprised, over and over and over.
"Late Wednesday, the Cambridge, Mass.-based biotech company posted net income for the third quarter that rose to $2.9 million, or 3 cents a share, from $1.4 million, or 1 cent, in the same period during fiscal 2006. Excluding certain items, Alkermes would have reported adjusted earnings of 11 cents a share. Revenue for the quarter jumped 51% to $62.4 million, up from $41.4 million. Analysts polled by Thomson Financial had expected a quarterly loss for Alkermes of a penny a share, on revenue of $55 million. "